Autolus Limited, a London, UK-based biopharmaceutical company focused on the development and commercialization of engineered T-cell therapies for haematological and solid tumours, raised £40m in Series B financing.
Backers included Woodford Investment Management LLP and Perceptive Bioscience Investments Ltd. In conjunction with the funding, Dr Joe Anderson, Chief Executive Officer of Perceptive Bioscience, joined the board of directors of Autolus.
The company intends to use the funds to develop its proprietary pipeline of engineered T-cell products, and to further implement its platform of T-cell programming technologies. In conjunction with the financing, the company’s technology platform was enhanced by a licence to additional technologies from UCL Business PLC, UCL’s (University College London) technology transfer company.
Led by Dr Christian Itin, Chairman, Autolus is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology.
Autolus is founded upon the work of Dr Martin Pule, an academic clinical haematologist at the UCL Cancer Institute and NIHR University College London Hospitals Biomedical Research Centre and a thought-leader in T-cell engineering.